Elimination of plasma soluble antigen in cynomolgus monkeys by combining pH-dependent antigen binding and novel Fc engineering

• Published in: mAbs Vol. 14; no. 1; p. 2068213
• Main Authors: Hori, Yuji, Ohmine, Ken, Katada, Hitoshi, Noguchi, Yuki, Sato, Kazuki, Nambu, Takeru, Adeline, Lam Runyi, Wan, Gan Siok, Haraya, Kenta, Ozeki, Kazuhisa, Nanami, Masahiko, Tachibana, Tatsuhiko, Sampei, Zenjiro, Kuramochi, Taichi, Nezu, Junichi, Hattori, Kunihiro, Igawa, Tomoyuki
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 2022; Taylor & Francis Group
• Subjects: Animals; antibody engineering; Antigen-Antibody Complex; Antigens; Fc engineering; FcγRIIb; Humans; Hydrogen-Ion Concentration; Immunoglobulin Fc Fragments; Macaca fascicularis; pH-dependent antigen-binding antibody; sweeping antibody; Word; antibody engineering; Word; charge engineering; cynomolgus monkey cross-reactive; sweeping antibody; pH-dependent antigen-binding antibody; FcγRIIb; Fc engineering
• ISSN: 1942-0862; 1942-0870
• DOI: 10.1080/19420862.2022.2068213

A conventional antibody targeting a soluble antigen in circulation typically requires a huge dosage and frequent intravenous administration to neutralize the antigen. This is because antigen degradation is reduced by the formation of antigen-antibody immune complexes, which escape from lysosomal degradation using neonatal Fc receptor (FcRn)-mediated recycling. To address this, we developed an antigen-sweeping antibody that combines pH-dependent antigen binding and Fc engineering to enhance Fc receptor binding. The sweeping antibody actively eliminates the plasma antigens by increasing the cellular uptake of the immune complex and dissociating the antigens in the acidic endosome for degradation. Strong antigen sweeping can reduce the dosage, potentially achieve higher efficacy, and expand the scope of antigen space available for targeting by antibodies. In this study, to further improve the sweeping efficacy, we developed a novel antibody Fc variant by enhancing Fcγ receptor IIb (FcγRIIb) binding and modulating charge characteristics for increased cellular uptake of the immune complex, together with enhancing FcRn binding for efficient salvage of the antigen-free antibodies. Our Fc variant achieved strong antigen sweeping in cynomolgus monkeys with antibody pharmacokinetics comparable to a wild-type human IgG antibody. The positive-charge substitutions enhanced uptake of the immune complex by FcγRIIb-expressing cells in vitro, which was completely inhibited by an anti-FcγRIIb antibody. This suggests that the strong in vivo sweeping efficacy improved by the charge engineering is more likely achieved by FcγRIIb-dependent uptake of the immune complex rather than nonspecific uptake. We expect this novel Fc engineering can maximize the antigen sweeping efficacy even in humans and create novel therapeutic antibodies that meet unmet medical needs for patients.